Clinuvel Pharmaceuticals Limited
Research Clinuvel Pharmaceuticals Limited (UR9) on Bullrun: market cap EUR 294.50M, P/E 15.0, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerUR9
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 294.50M
- P/E15.0
- Dividend yield0.6%
- Financial periodFY2025
- RevenueAUD 95.02M
- Revenue growth7.8%
- Net incomeAUD 36.17M
- Free cash flowAUD 40.80M
- Gross margin83.3%
Valuation Snapshot
latest market cap is EUR 294.50M; P/E is 15.0; dividend yield is 0.6%.
Peer valuation comparison
Latest P/E is 14.97x versus a Healthcare sector median of 24.46x (38.8% below).
Latest dividend yield is 0.58% versus a Healthcare sector median of 2.11% (72.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 95.02M | AUD 36.17M | AUD 40.80M | 83.3% | 0.72 | AUD 224.11M | AUD 528.53K | AUD 240.81M |
| FY2024 | AUD 88.18M | AUD 35.64M | AUD 31.48M | 88.6% | 0.7 | AUD 183.87M | AUD 879.78K | AUD 203.01M |
| FY2023 | AUD 78.32M | AUD 30.60M | AUD 35.88M | 88.8% | 0.59 | AUD 156.81M | AUD 999.87K | AUD 164.63M |
| FY2022 | AUD 65.72M | AUD 20.88M | AUD 39.44M | 84.0% | 0.4 | AUD 121.51M | AUD 1.26M | AUD 125.56M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | EUR 294.50M | 15.0 | 0.5% | 0.03 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.03 EUR, yield 0.6%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.03 AUD |
| FY2024 | 0.03 AUD |
| FY2023 | 0.03 AUD |
| FY2022 | 0.02 AUD |
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Clinuvel Pharmaceuticals Limited's market cap?
Clinuvel Pharmaceuticals Limited's market capitalization is EUR 294.50M.
What is Clinuvel Pharmaceuticals Limited's P/E ratio?
Clinuvel Pharmaceuticals Limited's price-to-earnings (P/E) ratio is 15.0.
Does Clinuvel Pharmaceuticals Limited pay a dividend?
Clinuvel Pharmaceuticals Limited has a dividend yield of 0.6%.
What does Clinuvel Pharmaceuticals Limited do?
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.